247 related articles for article (PubMed ID: 35751095)
1. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
2. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
[TBL] [Abstract][Full Text] [Related]
3. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
Dejeux E; Rønneberg JA; Solvang H; Bukholm I; Geisler S; Aas T; Gut IG; Børresen-Dale AL; Lønning PE; Kristensen VN; Tost J
Mol Cancer; 2010 Mar; 9():68. PubMed ID: 20338046
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
6. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
7. EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Breast; 2019 Feb; 43():74-80. PubMed ID: 30502641
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
10. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
14. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Nolen BM; Marks JR; Ta'san S; Rand A; Luong TM; Wang Y; Blackwell K; Lokshin AE
Breast Cancer Res; 2008; 10(3):R45. PubMed ID: 18474099
[TBL] [Abstract][Full Text] [Related]
15. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.
Li J; Wu MF; Lu HW; Chen Q; Lin ZQ; Wang LJ
Cancer Med; 2016 Aug; 5(8):1863-72. PubMed ID: 27350066
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival.
Buda A; Lissoni AA; Floriani I; Biagioli E; Gerardi C; Bonazzi C; Chiari S; Locatelli L; Dell'Anna T; Signorelli M; Mangioni C; Milani R
Int J Gynecol Cancer; 2015 Oct; 25(8):1468-75. PubMed ID: 26222484
[TBL] [Abstract][Full Text] [Related]
18. Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer. Preliminary results.
Vergine M; Scipioni P; Garritano S; Colangelo M; Di Paolo A; Livadoti G; Maturo A; Monti M
G Chir; 2013; 34(9-10):254-6. PubMed ID: 24629809
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Neoadjuvant
Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
[TBL] [Abstract][Full Text] [Related]
20. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
